GlassScriptPhysician profile
Andrew R Brookner
NPI 1629063888
$1,079.23
in general payments reported to CMS, 2019-2025
15 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.86 · 2020: $24.12 · 2023: $57.39 · 2024: $251 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $206.19 | 2025 | Izervay |
| Harrow Eye, LLC | $185.10 | 2025 | Triesence, Iheezo |
| Bausch & Lomb Americas INC. | $116.86 | 2024 | Xipere |
| Apellis Pharmaceuticals, INC. | $111.72 | 2025 | Syfovre |
| Genentech, INC. | $105.63 | 2024 | Vabysmo |
| Astellas Pharma Global Development | $82.50 | 2025 | Izervay |
| Genentech USA, INC. | $56.25 | 2023-2024 | Vabysmo |
| Kala Pharmaceuticals, INC. | $44.91 | 2019 | |
| Abbvie INC. | $36.71 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.60 | 2023 | Eylea Hd |
| Dompe US, INC. | $25.52 | 2025 | Oxervate |
| Notal Vision, INC. | $24.17 | 2025 | Foresee Home |
| Aerie Pharmaceuticals, INC. | $24.12 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.95 | 2019 | |
| Allergan, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Brookner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.